Xenetic Biosciences, Inc. Announces Executive Leadership Transition

Xenetic Biosciences, Inc. (NASDAQ: XBIO) has appointed James F. Parslow, the company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024. Parslow brings over 35 years of experience in financial and business leadership across various industries, including biotech.

James Parslow expressed confidence in the company's immune-oncology technologies targeting hard-to-treat cancers. He emphasized that the management change aims to focus resources on advancing the pipeline toward clinical studies and extending the company's cash runway.

Xenetic is advancing its DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other solid tumors. The company expects to report preclinical data before the end of the year.